Genetic diseases

#Bluebird Bio #Cell and gene therapy #Gene therapy #Genetic diseases #Mergers and acquisitions

New DDW Highlights podcast: 4 March 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It’s been a mixed bag of news for gene therapies this week, ranging from… Read More

#News

#Bluebird Bio #Cell and gene therapy #Gene therapy #Genetic diseases #Mergers and acquisitions

This week in drug discovery (24-28 February) 

News round-up for 23-28 February by DDW Senior Digital Content Editor Diana Spencer. It’s been a mixed bag of news for gene therapies this week, ranging from huge successes in treating sight impairment, cystic fibrosis and hearing loss, to the quick sale of a previously successful gene therapy… Read More

#News

A child with a cochlear implant
#Gene therapy #Genetic diseases #Hearing Loss #Paediatrics #Regeneron Pharmaceuticals

Latest DB-OTO results confirm hearing improvements

Regeneron Pharmaceuticals has revealed updated data for the investigational gene therapy DB-OTO from the Phase I/II CHORD trial in 12 children who have profound genetic hearing loss due to variants of the otoferlin (OTOF) gene.   These include 72-week results showing speech and development progress… Read More

#Editor's Choice #News

Child having an eye test
#Gene therapy #Genetic diseases #MeiraGTx #Ophthalmology #UCL

Gene therapy treats rare genetic sight impairment in the UK

Four young children have gained improvements in their vision following treatment with a new genetic medicine through Moorfields Eye Hospital and UCL Institute of Ophthalmology, with the support of MeiraGTx.  The children were born with a severe impairment to their sight due to a rare genetic deficiency… Read More

#News #Trending News

bluebird bio
#Gene therapy #Genetic diseases #Mergers and acquisitions

bluebird bio agrees to acquisition due to “financial challenges”

bluebird bio has entered into a definitive agreement to be acquired by global investment firms Carlyle and SK Capital Partners in collaboration with a team of highly experienced biotech executives.  The decision was made after a third and final denial by the Food & Drug Administration (FDA) of bluebird’s appeal… Read More

#Business & Investment #News #Trending News

Laboratory research
#Clinical trials #Genetic diseases #Rare disease #Washington University School of Medicine

New US centre for rare diseases to promote drug research

Washington University School of Medicine in St Louis has launched the Center for Rare, Undiagnosed and Genetic Diseases, supported by an $8.5 million grant from Children’s Discovery Institute (CDI), a partnership with St Louis Children’s Hospital, St Louis Children’s Hospital Foundation and WashU Medicine.   The new centre… Read More

#News

#Genetic diseases #Grifols #Lung disease #Phase II trial

Trials advance subcutaneous plasma therapy for AAT deficiency 

Grifols has finished recruiting the second cohort of its Phase I/II study evaluating two different doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%) as a subcutaneous (SC) option for the treatment of alpha1-antitrypsin (AAT) deficiency.  Cohort 2 patients will receive a 180mg/kg dose of SC Alpha-1… Read More

#News

#Applied Therapeutics #CNS #FDA #Genetic diseases #Rare disease

Patient groups urge FDA to reconsider govorestat rejection

The US Food and Drug Administration’s (FDA) decision not to approve govorestat, a central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI) for Classic Galactosemia, has been met with criticism from patient groups.  Govorestat is the only investigational treatment to be evaluated for Galactosemia, a rare genetic disease that can be… Read More

#News #Regulatory #Trending News

RNA
#Circio Holding #circular RNAs #Gene therapy #Genetic diseases #In vivo #mRNA

How does circVec technology compare to conventional mRNA? 

Circio has announced updated in vivo data that demonstrates a substantial durability advantage of Circio’s circVec technology over conventional mRNA expression. In addition, Circio has undertaken sequence optimisation resulting in a new circVec 2.2 design.   “The circVec 2.1 design is performing very well in… Read More

#News

RNA strand
#Circio Holding #circular RNAs #Gene therapy #Genetic diseases #In vivo #mRNA

Data demonstrates superiority of circular RNA vs linear mRNA

In vivo proof-of-concept for Circio Holding’s differentiated circVec platform approach to gene therapy has been demonstrated in two posters at the American Society of Gene & Cell Therapy (ASGCT) 2024 annual meeting. The in vivo data showed statistically significant higher expression level and durability for circVec… Read More

#News

Child having a hearing test
#Gene mutation #Gene therapy #Genetic diseases #Hearing Loss #Paediatrics #Rare disease

Gene therapy cures profound genetic deafness within 24 weeks

The investigational gene therapy DB-OTO improved hearing to normal levels in a child (dosed at 11 months of age) within 24 weeks, according to trial data presented at the American Society of Gene and Cell Therapy (ASGCT) annual conference. Initial hearing improvements have also been observed… Read More

#News #Trending News

RNA strand
#Antisense Oligonucleotides (ASOs) #CAMP4 Therapeutics #CNS #Genetic diseases #mRNA #RNA #Turning Science into Business

Turning science into business: Amplifying mRNA by targeting regRNAs

DDW’s Diana Spencer speaks to Josh Mandel-Brehm, CEO of Massachusetts-based biotech CAMP4, to understand the role regulatory RNAs play in gene expression and how the founders overcame the challenge of launching a business based on brand new science. DS: CAMP4 leverages research from co-founder Richard Young on how regulatory RNA… Read More

#Business & Investment #Exclusive Content

Doctor prepares vaccine
#Cancer vaccine #Genetic diseases #ImmunityBio #Immunology / Virology & Vaccines #Oncology #Phase II trial

Combination cancer vaccine to be assessed in Phase II trial

The first 20 participants have been enrolled in a multicentre trial to test whether ImmunityBio’s Nant Cancer Vaccine (NCV) could potentially prevent colon and other cancers in individuals with Lynch syndrome. The vaccine comprises a tri-valent Adenovirus (Tri-Ad5) in combination with the company’s IL-15 superagonist N-803. Read More

#Cancer Research #News

Enzymes
#Chiesi #Enzymes #Genetic diseases #National Institute for Health and Care Excellence (NICE) #Rare disease

NICE okays enzyme replacement therapy for alpha-mannosidosis

Chiesi’s Lamzede (velmanase alfa) will now be funded on the NHS in England and Wales as an option for treating the non-neurological signs and symptoms of mild to moderate alpha-mannosidosis following a recommendation by the National Institute for Health and Care Excellence (NICE). The treatment must be started in people… Read More

#News #Regulatory

Blood cells
#FDA #Gene mutation #Genetic diseases #Rare disease #Takeda

First therapy for very rare blood clotting disorder gets US greenlight

Takeda’s Adzynma has become the first recombinant protein product approved in the US for prophylactic or on-demand enzyme replacement therapy (ERT) for congenital thrombotic thrombocytopenic purpura (cTTP). A very rare, inherited blood clotting disorder, cTTP is caused by a disease-causing mutation in the ADAMTS13 gene, which is responsible for making… Read More

#Editor's Choice #News #Regulatory

#Biopharma #Cell line development #Cell lines #FDA #Genetic diseases #Genetics #R&D

New podcast: Challenges and tactics for drug development

This is the latest episode of the free DDW narrated podcast, “Challenges and tactics for transformative drug development”. It covers two articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Balancing speed and quality in CLD for faster drug development”, and… Read More

#News